Quick Answer
Bionano Genomics, Inc. reported Total Revenue of $28.51 million for fiscal year 2025.
Bionano Genomics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $28.51M -7.4% |
$30.78M -14.8% |
$36.12M +29.9% |
$27.80M +54.6% |
$17.98M +111.5% |
$8.50M -16.1% |
| Revenue (ASC 606) | $28.51M -7.4% |
$30.78M -14.8% |
$36.12M +29.9% |
$27.80M +54.6% |
$17.98M +111.5% |
$8.50M -16.1% |
| Net Income | -$26.39M +76.4% |
-$112.02M +51.8% |
-$232.49M -75.3% |
-$132.60M -83.1% |
-$72.44M -76.2% |
-$41.11M -37.9% |
| Diluted EPS | -$4.85 +94.5% |
-$88.13 +78.4% |
-$408.60 -8821.4% |
-$4.58 -1661.5% |
-$0.26 | — |
| Total Assets | $73.58M -4.0% |
$76.67M -64.2% |
$214.40M -30.3% |
$307.50M -18.5% |
$377.10M +523.8% |
$60.45M +100.1% |
| Cash and Equivalents | $2.99M -67.4% |
$9.17M -48.9% |
$17.95M +252.5% |
$5.09M -79.3% |
$24.57M -36.1% |
$38.45M +122.1% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$16.32M |
| Stockholders Equity | $44.42M +25.6% |
$35.38M -63.2% |
$96.16M -61.4% |
$249.40M -26.0% |
$337.12M +860.9% |
$35.08M +871.0% |
| R&D Expense | $11.37M -54.1% |
$24.80M -54.1% |
$54.03M +10.2% |
$49.05M +118.1% |
$22.48M +119.2% |
$10.26M +12.9% |
| Operating Income | -$33.34M +67.9% |
-$103.98M +51.7% |
-$215.25M -63.4% |
-$131.70M -70.8% |
-$77.10M -100.0% |
-$38.55M -49.0% |
| Shares Outstanding | 10.74M +475.8% |
1.87M +144.6% |
762,533 -97.4% |
29.72M -89.7% |
289.60M +52.5% |
189.95M +454.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $7.37M | +21.3% | +9.4% |
| Revenue (ASC 606) | September 30, 2025 | $7.37M | +21.3% | +9.4% |
| Net Income | September 30, 2025 | -$8.50M | +80.8% | -24.0% |
| Diluted EPS | September 30, 2025 | -$1.59 | +94.9% | +20.1% |
| Total Assets | September 30, 2025 | $79.06M | -9.5% | +4.0% |
| Cash and Equivalents | September 30, 2025 | $3.06M | -65.1% | -14.0% |
| Long-Term Debt | September 30, 2021 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $49.80M | +1.9% | +9.8% |
| R&D Expense | September 30, 2025 | $2.84M | -39.7% | -3.0% |
| Operating Income | September 30, 2025 | -$8.54M | +80.6% | -9.5% |
| Shares Outstanding | September 30, 2025 | 9.73M | -89.0% | +148.9% |
- Bionano Genomics, Inc. reported Total Revenue of $28.51 million for fiscal year 2025.
- Bionano Genomics, Inc. showed a decrease of -7.4% in Total Revenue compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Revenue (ASC 606) of $28.51 million for fiscal year 2025.
- Bionano Genomics, Inc. showed a decrease of -7.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Net Income of -$26.39 million for fiscal year 2025.
- Bionano Genomics, Inc. showed an increase of +76.4% in Net Income compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Diluted EPS of $4.85 per share (loss) for fiscal year 2025.
- Bionano Genomics, Inc. showed an increase of +94.5% in Diluted EPS compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Total Assets of $73.58 million for fiscal year 2025.
- Bionano Genomics, Inc. showed a decrease of -4.0% in Total Assets compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Cash and Equivalents of $2.99 million for fiscal year 2025.
- Bionano Genomics, Inc. showed a decrease of -67.4% in Cash and Equivalents compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- Bionano Genomics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Stockholders Equity of $44.42 million for fiscal year 2025.
- Bionano Genomics, Inc. showed an increase of +25.6% in Stockholders Equity compared to the prior fiscal year.
- Bionano Genomics, Inc. reported R&D Expense of $11.37 million for fiscal year 2025.
- Bionano Genomics, Inc. showed a decrease of -54.1% in R&D Expense compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Operating Income of -$33.34 million for fiscal year 2025.
- Bionano Genomics, Inc. showed an increase of +67.9% in Operating Income compared to the prior fiscal year.
- Bionano Genomics, Inc. reported Shares Outstanding of 10.74 million shares for fiscal year 2025.
- Bionano Genomics, Inc. showed an increase of +475.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: